DE68922358D1 - Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. - Google Patents

Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen.

Info

Publication number
DE68922358D1
DE68922358D1 DE68922358T DE68922358T DE68922358D1 DE 68922358 D1 DE68922358 D1 DE 68922358D1 DE 68922358 T DE68922358 T DE 68922358T DE 68922358 T DE68922358 T DE 68922358T DE 68922358 D1 DE68922358 D1 DE 68922358D1
Authority
DE
Germany
Prior art keywords
pct
fibrinogen
fibronectin
factor
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68922358T
Other languages
English (en)
Other versions
DE68922358T3 (de
DE68922358T2 (de
Inventor
Thierry Burnouf
Myriana Burnouf Myrian Burnouf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Original Assignee
CENTRE REGIONAL DE TRANSFUSION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9367001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68922358(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CENTRE REGIONAL DE TRANSFUSION filed Critical CENTRE REGIONAL DE TRANSFUSION
Application granted granted Critical
Publication of DE68922358D1 publication Critical patent/DE68922358D1/de
Publication of DE68922358T2 publication Critical patent/DE68922358T2/de
Publication of DE68922358T3 publication Critical patent/DE68922358T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE68922358T 1988-06-07 1989-02-08 Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. Expired - Lifetime DE68922358T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8807530 1988-06-07
FR8807530A FR2632309B1 (fr) 1988-06-07 1988-06-07 Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Publications (3)

Publication Number Publication Date
DE68922358D1 true DE68922358D1 (de) 1995-06-01
DE68922358T2 DE68922358T2 (de) 1995-10-12
DE68922358T3 DE68922358T3 (de) 2004-08-19

Family

ID=9367001

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198989400348T Pending DE359593T1 (de) 1988-06-07 1989-02-08 Chromatographische trennung von plasmaproteinen.
DE68922358T Expired - Lifetime DE68922358T3 (de) 1988-06-07 1989-02-08 Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE198989400348T Pending DE359593T1 (de) 1988-06-07 1989-02-08 Chromatographische trennung von plasmaproteinen.

Country Status (17)

Country Link
US (1) US5252709A (de)
EP (1) EP0359593B2 (de)
JP (1) JP2805364B2 (de)
KR (1) KR970010923B1 (de)
AT (1) ATE121750T1 (de)
AU (2) AU622436B2 (de)
CA (1) CA1340742C (de)
DE (2) DE359593T1 (de)
DK (1) DK175322B1 (de)
ES (1) ES2070919T5 (de)
FI (1) FI96210C (de)
FR (1) FR2632309B1 (de)
LT (1) LT3333B (de)
NO (1) NO177188C (de)
RU (1) RU1837880C (de)
UA (1) UA11061A (de)
WO (1) WO1989012065A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
NL9000090A (nl) * 1990-01-15 1991-08-01 Harimex Ligos Bv Werkwijze voor het bereiden van een fibrinogeenconcentraat uit bloedplasma, inrichting voor het uitvoeren van deze werkwijze en werkwijze voor het bereiden van fibrinogeen uit het concentraat.
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4202667C1 (de) * 1992-01-29 1993-05-13 Behringwerke Ag, 3550 Marburg, De
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
ES2139227T5 (es) * 1994-07-14 2011-05-04 Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación.
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
ES2145466T3 (es) * 1996-06-24 2000-07-01 Max Planck Inst Fur Physiologi Procedimiento para la purificacion del factor viii por cromatografia de afinidad.
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
SG150501A1 (en) * 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
FR2885369B1 (fr) * 2005-05-04 2010-11-12 Lab Francais Du Fractionnement Materiel infectieux synthetique et standardise de type prion et ses utilisations en tant qu'inoculum infectant.
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
WO2009145722A1 (en) * 2008-05-30 2009-12-03 Ge Healthcare Bio-Sciences Ab Separation method utilizing polyallylamine ligands
HUE028626T2 (en) 2008-06-23 2016-12-28 Bio-Products & Bio-Engineering Ag Stable, functionally intact, virus-inactivated fibrinogen during storage
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
FR2952641B1 (fr) 2009-11-18 2012-01-13 Lfb Biomedicaments Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion
BR112012017696A2 (pt) 2010-01-18 2017-10-03 Novo Nordisk Healthcare Ag Purificação de fatores de coagulação de sangue
RU2445974C2 (ru) * 2010-04-26 2012-03-27 Учреждение Российской академии медицинских наук Гематологический научный центр ГНЦ РАМН Способ получения концентрата фактора viii из плазмы крови человека
EP2652491B1 (de) 2010-12-15 2017-11-29 Baxalta GmbH Eluatsammlung mit leitfähigkeitsgradient
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) * 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2019050321A1 (ko) * 2017-09-07 2019-03-14 (주)프로테옴텍 다수의 검사선을 구비한 크로마토그래피용 스트립, 이를 포함하는 진단 키트 및 다수의 경쟁적 반응 측정 단계를 포함하는 정성, 반정량, 정량 분석방법
EP3488858A1 (de) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies Eine von-willebrand-faktor-zusammensetzung und deren verwendung zur behandlung einer durch angiogenese verursachte krankheit

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278594A (en) * 1979-06-19 1981-07-14 David Amrani Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma
EP0022053A1 (de) * 1979-06-25 1981-01-07 Rexnord Inc. Gegenschneide mit eingekerbter Schnittkante
US4341764A (en) * 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
FR2570276B1 (fr) * 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
JPS61189228A (ja) * 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
EP0235526A3 (de) * 1986-01-29 1988-03-23 Leipziger Arzneimittelwerk GmbH Aktivierte Polymerfestkörper und Verfahren zu ihrer Herstellung
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5097018A (en) * 1988-05-12 1992-03-17 University Of Southern California Sequential heat treatment of blood-clotting factor products
NL8701915A (nl) * 1987-08-14 1989-03-01 Waander Riethorst Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren.
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
IT1306645B1 (it) 1999-04-08 2001-10-02 Challenger Gestao E Consultado Struttura di sedia, poltroncina o simile ad assemblaggio facilitato.

Also Published As

Publication number Publication date
ES2070919T3 (es) 1995-06-16
DE68922358T3 (de) 2004-08-19
KR970010923B1 (ko) 1997-07-02
DK175322B1 (da) 2004-08-23
FR2632309A1 (fr) 1989-12-08
NO177188B (no) 1995-04-24
FR2632309B1 (fr) 1990-08-24
UA11061A (uk) 1996-12-25
EP0359593B1 (de) 1995-04-26
AU622436B2 (en) 1992-04-09
DK29990D0 (da) 1990-02-06
ES2070919T5 (es) 2004-07-16
FI96210B (fi) 1996-02-15
EP0359593B2 (de) 2004-01-07
NO177188C (no) 1995-08-02
DK29990A (da) 1990-03-28
FI96210C (fi) 1996-05-27
DE359593T1 (de) 1990-09-27
LT3333B (en) 1995-07-25
WO1989012065A1 (fr) 1989-12-14
KR900701823A (ko) 1990-12-04
CA1340742C (fr) 1999-09-14
ATE121750T1 (de) 1995-05-15
NO900529L (no) 1990-04-06
EP0359593A1 (de) 1990-03-21
AU3068289A (en) 1990-01-05
NO900529D0 (no) 1990-02-05
LTIP262A (en) 1994-10-25
RU1837880C (ru) 1993-08-30
US5252709A (en) 1993-10-12
FI900397A0 (fi) 1990-01-25
DE68922358T2 (de) 1995-10-12
JP2805364B2 (ja) 1998-09-30
JPH03501974A (ja) 1991-05-09
AU1138392A (en) 1992-05-14

Similar Documents

Publication Publication Date Title
ATE121750T1 (de) Chromatographische trennung von plasmaproteinen, insbesondere von faktor viii, von willebrand faktor, von fibronectin und von fibrinogen.
Burnouf Chromatography in plasma fractionation: benefits and future trends
Fearon Purification of C3b inactivator and demonstration of its two polypeptide chain structure
ES8501979A1 (es) Procedimiento para preparar un concentrado de factor antihemofilico
FI963197A (fi) Laktoferriinin eristäminen maidosta
IL76929A (en) Preparation for the treatment of hemophilia a inhibitor patients and processes for producing such a preparation
DK158281C (da) Fremgangsmaade til fremstilling af et faktor viii (ahf)-holdigt praeparat
DE69024105T2 (de) Verfahren zur Herstellung von gereinigten Albuminlösungen
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
DE69433682T2 (de) Wässrige proteinzusammensetzung, enthaltend glykoproteine, verfahren zur herst ellung und verwendungen
HU896448D0 (en) Process for the preparation of anticoagulant peptides
EP0723016A3 (de) Leukocyten-aktivierender Faktor
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat
Zimmerman et al. Purification of factor VIII by monoclonal antibody affinity chromatography

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8310 Action for declaration of annulment
8327 Change in the person/name/address of the patent owner

Owner name: L'ASSOCIATION POUR L'ESSOR DE LA TRANSFUSION SANGU